Senesco To Present At NYSSA's 2011 Biotech / Specialty Pharma Conference
Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT)
announced that the Company will be presenting at NYSSA's 2011 Biotech /
Specialty Pharma Conference being held at The Conference...
Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced that the Company will be presenting at NYSSA's 2011 Biotech / Specialty Pharma Conference being held at The Conference Facilities of The New York Society of Security Analysts in New York City at 1540 Broadway, Suite 1010. Leslie J. Browne, Ph.D., President and CEO of Senesco, will deliver the Company’s corporate presentation and provide an update on recent non-clinical and clinical findings with SNS01-T on Wednesday, November 30 th, at 11.05 a.m. (Eastern Time). An archived webcast of Dr. Browne’s presentation will be available on the NYSSA’s website at www.nyssa.org after December 14, 2011. Senesco recently initiated patient dosing at the Mayo Clinic in Rochester, MN, in a Phase 1b/2a clinical study of SNS01-T, the Company’s lead therapeutic candidate for the treatment of multiple myeloma, and also indicated its plan to initiate in 2012 an additional clinical study of SNS01-T in other B-cell cancers. The Company has demonstrated in the laboratory that SNS01-T can significantly inhibit the growth of both human mantle cell and diffuse large B-cell lymphomas in a dose dependent manner in mouse xenograft models. Potential additional effectiveness was observed from in vitro studies in which SNS01-T was combined with other approved myeloma drugs. “We believe we have shown that certain myeloma drugs can be up to 40 times more potent in vitro when used in combination with SNS01-T,” stated Leslie J. Browne, Ph.D., President and CEO of Senesco. “Together these results further reinforce the significance of our target, eIF5A, and will guide us in designing our future clinical studies.” About Multiple Myeloma Multiple myeloma is an incurable cancer of plasma cells, a type of white blood cell derived from B-lymphocytes, normally responsible for the production of antibodies. Malignant plasma cells accumulate in the bone marrow leading to bone lesions and interfering with the production of normal white blood cells. Median survival time from first treatment is 2½ to 5 years depending on disease stage at diagnosis. In the United States there are approximately 20,000 newly diagnosed cases of multiple myeloma annually and a total of approximately 65,000 patients with the disease. Senesco was previously granted orphan drug status for SNS01-T, the Company’s lead drug candidate for treatment of multiple myeloma.